From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: GSK

Search articles by EPIC code

Big Developments for this Giant Pharma could Soon Mean a Healthier Share Price

Hello Share Tempters. There are two very big British pharmas you could invest in. A long time ago I chose GlaxoSmithKline (GSK), rather than AstraZeneca (AZN). I sometimes regret that choice as AstraZeneca seems to have been the more dynamic company, including with a Covid vaccine for example. But I would not swap holdings now, as I think things are happening at GSK that could improve its share price.


How much will GlaxoSmithKline shareholders love Haleon?

If you are a GlaxoSmithKline (GSK) investor, you may have noted last week that the FTSE-100 company observed the new name for its consumer health business ‘Haleon’ is from “Hale” (meaning in good health) and “Leon” (which it claimed was associated with strength) and declared it was to be pronounced “Hay-Lee-On”. Enjoy mispronouncing that! Of course the urban dictionary’s definition is a little bit alternative to this… So should GlaxoSmithKline’s shareholders be excited or concerned about July’s upcoming business split of the consumer health and core pharmaceutical business?


Marmite King Versus the Panadol Prince. There Could Be Money to be Made here, Gang

Hello Share Shovers. You’ll either love this possible takeover - or hate it. The owner of Marmite is rumoured to very much want to snaffle the giant consumer arm of GlaxoSmithKline (GSK). And Unilever (ULVR) actually made a £50 billion approach. This was turned down as being too low. As an owner of GSK shares, I agree that it wasn’t an enticing proposition and I expect a bigger one to come.


Still loving GlaxoSmithKline as Unilever bid emerges

I was already excited about the upcoming week, predominately because a bunch of interesting companies are giving us an update on Monday, Tuesday, Wednesday, Thursday, and Friday.  So maybe an existing holding does well or maybe I get an opportunity to consider a new angle.  One stock I am going to be watching closely on Monday morning is GlaxoSmithKline (GSK) as I read that ‘Unilever(ULVR) makes £50 billion bid for GSK’s consumer business’. 


GlaxoSmithKline – good news as it hires ‘Tesco Dave’

Markets might be a bit volatile today but such is life in the investment world. Anyhow, some good news for us current GlaxoSmithKline (GSK) shareholders as the company has ‘announced that Sir Dave Lewis has been appointed as Non-Executive Chair Designate of the new Consumer Healthcare company which will result from the proposed demerger from GSK in 2022…his appointment will take effect from 1st January 2022’. Good news as Dave Lewis was a legend over his time at Tesco (TSCO), a super successful turnaround he exited as CEO last year. It is always smart to exit stage left when the crowd is asking for more, and I am not surprised too he has taken a Chair role rather than a CEO one.

Page 2 of 7 (66 articles)
Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Complete Coverage

Recent Comments